Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells 17,500 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) Director Molly Harper sold 17,500 shares of the firm's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Catalyst Pharmaceuticals Trading Down 1.2 %

NASDAQ:CPRX traded down $0.27 during midday trading on Friday, hitting $22.07. 554,323 shares of the company were exchanged, compared to its average volume of 1,187,151. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.00 and a fifty-two week high of $24.27. The company has a market capitalization of $2.63 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 3.44 and a beta of 0.75. The company has a fifty day simple moving average of $21.23 and a 200 day simple moving average of $18.72.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several research analyst reports. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an "overweight" rating and a $35.00 price target for the company. Truist Financial raised their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Finally, Citigroup boosted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $31.14.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CPRX. Arizona State Retirement System increased its holdings in shares of Catalyst Pharmaceuticals by 2.2% in the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company's stock valued at $461,000 after purchasing an additional 654 shares during the period. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 681 shares during the period. XTX Topco Ltd increased its stake in Catalyst Pharmaceuticals by 7.5% in the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company's stock valued at $172,000 after buying an additional 773 shares during the period. Strategic Advocates LLC raised its position in Catalyst Pharmaceuticals by 6.5% during the 2nd quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 864 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in shares of Catalyst Pharmaceuticals by 1.3% in the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company's stock worth $1,308,000 after acquiring an additional 1,098 shares during the period. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.